Analysis of new clinical data revealed that patients who have heart disease and chronic kidney disease who took Lipitor® (atorvastatin calcium) Tablets (80 mg) reduced their risk of heart attack and stroke by 32% compared with patients taking the 10 mg dose of Lipitor.
This finding came from a subset of patients from the five-year TNT (Treating to New Targets) study just presented at the Annual Scientific Sessions of the American Heart Association.
According to Dr. James Shepherd, a member of the TNT steering committee and clinical academic consultant, department of pathological biochemistry, University of Glasgow Medical School:
"These findings show that more aggressive treatment with Lipitor in patients with kidney disease can help reduce the risk of heart attack and stroke and improve measures of kidney function.
The analysis suggests the expected decline in kidney function that occurred over time could be arrested with Lipitor 10 mg and, in fact, was reversed with Lipitor 80 mg therapy.
This study is the first to show this type of dose- dependent effect with Lipitor."
The famous Lipitor® is a product of Pfizer, Inc. (NYSE: PFE)
Find more details of the clinical data from the Pfizer press release.
Comment Preview